PSTV Q1 EPS Forecast Reduced by Ascendiant Capital Markets

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Ascendiant Capital Markets dropped their Q1 2026 earnings per share estimates for Plus Therapeutics in a note issued to investors on Wednesday, April 8th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings per share of ($0.89) for the quarter, down from their prior estimate of ($0.75). Ascendiant Capital Markets has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. Ascendiant Capital Markets also issued estimates for Plus Therapeutics’ Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.56) EPS and FY2027 earnings at ($2.69) EPS.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings results on Thursday, March 12th. The company reported $6.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $6.28. The company had revenue of $1.37 million during the quarter, compared to the consensus estimate of $1.23 million.

Several other equities research analysts have also weighed in on PSTV. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price (down from $50.00) on shares of Plus Therapeutics in a report on Friday, January 23rd. Lake Street Capital started coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $50.00 price objective for the company. Wall Street Zen raised Plus Therapeutics to a “sell” rating in a research note on Saturday, April 4th. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Plus Therapeutics presently has an average rating of “Hold” and an average target price of $58.00.

Plus Therapeutics Stock Performance

Shares of NASDAQ PSTV opened at $5.65 on Wednesday. The stock has a market cap of $38.76 million, a P/E ratio of -0.18 and a beta of 1.03. The firm has a 50 day moving average price of $6.14 and a 200 day moving average price of $10.96. Plus Therapeutics has a 52-week low of $2.90 and a 52-week high of $30.50.

Institutional Investors Weigh In On Plus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Susquehanna International Group LLP bought a new stake in Plus Therapeutics in the 3rd quarter valued at approximately $46,000. Jane Street Group LLC bought a new position in shares of Plus Therapeutics during the 2nd quarter worth approximately $41,000. State Street Corp raised its holdings in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the last quarter. Scientech Research LLC acquired a new stake in shares of Plus Therapeutics in the third quarter valued at approximately $100,000. Finally, XTX Topco Ltd bought a new stake in shares of Plus Therapeutics in the fourth quarter worth $127,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics News Summary

Here are the key news stories impacting Plus Therapeutics this week:

• Positive Sentiment: Plus Therapeutics appointed Randy H. Goodman, PhD, MHA as Vice President of Value Strategy & HEOR to lead payer strategy, value-based pricing and reimbursement planning aimed at advancing market access and commercialization of CNSide / REYOBIQ™ — a hire that can help reduce reimbursement barriers and support launch economics. Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA
• Neutral Sentiment: Technical/context: the shares are trading up with volume slightly below average; the 50-day SMA (~$6.15) remains well below the 200-day SMA (~$11.00), and the stock sits between its 52-week low ($2.90) and high ($30.50) — indicating lingering longer-term weakness despite short-term buying interest.
• Negative Sentiment: Ascendiant Capital Markets cut EPS forecasts across 2026 quarters and widened FY2026 loss expectations (FY2026 now forecast at about ($3.56) vs prior ($3.25)), lowering quarterly estimates (many moved from about ($0.75) to ($0.89) per quarter) while maintaining a “Buy” rating and a $65 price target — the bigger expected losses may pressure near-term sentiment despite the long-term bullish target. MarketBeat: Ascendiant Capital Markets analyst update

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.